INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is one of the major causes of morbidity and mortality worldwide, and is characterized by persistent airflow limitation, which is associated with an enhanced chronic inflammatory response to noxious particles or gases in the airways and the lung. The current pharmacological treatment of COPD is mainly symptomatic and focuses on bronchodilators, such as inhaled β2-adrenergic agonists and anticholinergics. Inhaled corticosteroids (ICS) improve lung function, symptoms, and quality of life and reduce the frequency of exacerbations in COPD patients with a forced expiratory volume in 1 second (FEV1) of <60% predicted. However, ICS are associated with a greater prevalence of oral candidiasis and hoarse voice, as well as an increased risk of pneumonitis. Thus, an orally active non-steroidal anti-inflammatory agent is needed for patients with COPD. Phosphodiesterase 4 (PDE4), an isoenzyme of the PDE family, is the major regulator of cyclic adenosine monophosphate present in the inflammatory cells of the airway that are involved in the pathogenesis of COPD. Roflumilast has demonstrated modest improvements in lung function and reduced the frequency of exacerbations in patients with COPD. However, roflumilast also has significant adverse effects, primarily gastrointestinal and psychiatric prob-

Efficacy and Safety of Roflumilast in Korean Patients with COPD

Jae Seung Lee¹, Yoon Ki Hong², Tae Sun Park¹, Sei Won Lee¹, Yeon-Mok Oh¹, and Sang-Do Lee¹

¹Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul; ²Department of Internal Medicine, Kangwon National University College of Medicine, Chuncheon, Korea.

Purpose: Roflumilast is the only oral phosphodiesterase 4 inhibitor approved to treat chronic obstructive pulmonary disease (COPD) patients [post-bronchodilator forced expiratory volume in 1 second (FEV1) <50% predicted] with chronic bronchitis and a history of frequent exacerbations. This study evaluated the efficacy and safety of roflumilast in Korean patients with COPD and compared the efficacy based on the severity of airflow limitation.

Materials and Methods: A post-hoc subgroup analysis was performed in Korean COPD patients participating in JADE, a 12-week, double-blinded, placebo-controlled, parallel-group, phase III trial in Asia. The primary efficacy endpoint was the mean [least-squares mean adjusted for covariates (LSMean)] change in post-bronchodilator FEV1 from baseline to each post-randomization visit. Safety endpoints included adverse events (AEs) and changes in laboratory values, vital signs, and electrocardiograms.

Results: A total of 260 Korean COPD patients were recruited, of which 207 were randomized to roflumilast (n=102) or placebo (n=105) treatment. After 12 weeks, LSMean post-bronchodilator FEV1 increased by 43 mL for patients receiving roflumilast and decreased by 60 mL for those taking placebo. Adverse events were more common in the roflumilast group than in the placebo group; however, the types and frequency of AEs were comparable to those reported in previous studies.

Conclusion: Roflumilast significantly improved lung function with a tolerable safety profile in Korean COPD patients irrespective of the severity of airflow limitation.

Key Words: Chronic obstructive pulmonary disease, Korea, roflumilast, treatment efficacy, safety

Received: June 24, 2015 Revised: November 3, 2015 Accepted: November 17, 2015

Corresponding author: Dr. Sang-Do Lee, Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. Tel: 82-2-3010-3140, Fax: 82-2-3010-6968, E-mail: sdlee@amc.seoul.kr

© Copyright: Yonsei University College of Medicine 2016

This is an Open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
lems. Recently, roflumilast received restricted approval by both the US and Korean Food and Drug Administrations for the treatment of severe COPD (post-bronchodilator FEV$_1$ <50% predicted) and chronic bronchitis in patients who have a history of frequent exacerbations. Previous studies of roflumilast have predominantly involved Caucasian populations. However, ethnic differences may contribute to differences in drug responses and cause unexpected therapeutic and adverse effects. Thus, further study is necessary to determine the efficacy and safety of roflumilast in Korean COPD patients. The JADE study, a phase III randomized trial, investigated the effect of roflumilast on pulmonary function in Asian patients with COPD. This post-hoc subgroup analysis evaluated the efficacy and safety of roflumilast in a Korean population and compared the efficacy among subgroups based on the Korean COPD classification guidelines.

MATERIALS AND METHODS

Patients and study design
The JADE study (ClinicalTrials.gov identifier NCT00242320) was a 12-week, double-blinded, placebo-controlled, parallel-group, phase III trial of roflumilast conducted in 35 outpatient centers in South Korea, Hong Kong, Malaysia, Philippines, and Taiwan. Korean COPD patients were recruited from 15 tertiary university hospitals. The study was approved by the Institutional Review Board or Independent Ethics Committee at each center, and all patients gave written informed consent. The inclusion criteria and main results of the study have been published previously. Key inclusion criteria included adults aged ≥40 years with a history of COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (post-bronchodilator FEV$_1$/forced vital capacity ≤70%, post-bronchodilator FEV$_1$, 30–80% predicted, and FEV$_1$ increase ≤15% and/or ≤200 mL after receiving 400 μg salbutamol). Eligible patients were stratified according to smoking status and then randomized to receive either roflumilast (500 μg) or placebo once daily. A single-blind 4-week run-in period was followed by a double-blind 12-week treatment period. Pre- and post-bronchodilator spirometry was performed at the start of the run-in period and repeated at baseline and at 4, 8, and 12 weeks during the treatment period. Patients were not allowed to take ICS, inhaled long-acting β$_2$ agonists, oral β$_2$ agonists, and inhaled long-act-
ing anticholinergics during the treatment period, although salbutamol was allowed as a rescue medication. Medication history, routine physical examination, chest radiograph, resting 12-lead electrocardiogram, standard laboratory tests, vital signs, and smoking status were assessed at each visit. Patients were withdrawn from the study if they experienced a severe exacerbation or two moderate exacerbations during the treatment period. The primary efficacy endpoint was the mean [least-squares mean adjusted for covariates (LSMean)] change in post-bronchodilator FEV₁, from baseline to each post-randomization visit. Secondary efficacy endpoints included the mean changes in pre- and post-bronchodilator spirometric parameters from baseline to each post-randomization visit and rate of exacerbation. Safety endpoints included adverse events (AEs), changes in laboratory values, and changes in vital signs and electrocardiograms.

Statistical analysis
Data are presented as mean and standard deviation (SD) unless otherwise indicated. Comparisons between groups were assessed using Student’s t-test or the Mann-Whitney U test for continuous variables except for lung function endpoints, or χ² or Fisher’s exact test for categorical variables. Efficacy data were analyzed by intention to treat (ITT) in randomized patients receiving at least one dose of study medication. The per-protocol (PP) population was comprised of patients in the ITT population who had no documented major study protocol violations. Lung function changes were analyzed using a repeated-measures analysis of covariance (ANCOVA) for all visits from baseline to the final scheduled visit at week 12. Additionally, supportive analyses were performed using an ANCOVA model with the last observation carried forward. LS means for each treatment and the difference between treatments were calculated together with the corresponding 95% confidence interval (CI) and two-sided p-values. Safety analyses were assessed in all randomized patients who took at least one dose of the trial treatment, and patients were analyzed under the treatment they actually received. Adverse events were compared using χ² or Fisher’s exact tests. All statistical analyses were carried out using SAS for Windows XP, Version 9.1.3 (SAS Institute, Cary, NC, USA) or PROC StatXact (for nonparametric analyses) for SAS (Version 6.2, SAS Institute).

RESULTS

Demographics of study participants
A total of 260 Korean COPD patients were recruited. Of these patients, 207 (male, n=206) were randomized to roflumilast (n=102) or placebo (n=105) and included in the ITT and safety analyses. All but one randomized patient were male. A total of 72 patients in the roflumilast group and 74 patients in the placebo group had post-bronchodilator FEV₁ <60% predicted. Of the 207 randomized patients, 181 completed the study, and 164 were included in the PP analyses (roflumilast, n=79; placebo, n=85) (Fig. 1). Of the 164 patients, the mean (SD) age was 66.9 (7.3) years, the mean body mass index was 22.6 (2.8) kg/m², and the mean post-bronchodilator FEV₁ was 51.7% (13.9) of the predicted value, respectively. No significant differences in baseline demographic characteristics or spirometric parameters were observed between groups (Table 1).

Efficacy analysis
The primary endpoint (LSMean post-bronchodilator FEV₁) increased by 43 mL in patients receiving roflumilast and decreased by 60 mL in those receiving placebo after 12 weeks of treatment (Table 2). The inter-treatment difference of 103 mL was statistically significant (p<0.0001), demonstrating the superiority of roflumilast for improving post-bronchodilator FEV₁ in patients with COPD. Similar analyses of LSNPre-bronchodilator FEV₁ also demonstrated the superiority of roflumilast over placebo (inter-treatment difference: 119 mL, 95% CI 61–153 mL, p<0.001). Furthermore, differences in pre- and post-bronchodilator FEV₁ were observed between roflumilast- and placebo-treated patients after 4 weeks of treatment and were

Table 1. Baseline Characteristics of Korean COPD Patients in the JADE Study

| Variable                        | Roflumilast (n=102) | Placebo (n=105) | p value |
|---------------------------------|---------------------|-----------------|---------|
| Gender, male, n (%)*            | 102 (100.0)        | 104 (99.0)      | 0.32    |
| Age (yrs)                       | 66.9±6.95          | 66.9±7.71       | 0.99    |
| Body mass index (kg/m²)         | 22.9±2.90          | 22.4±2.68       | 0.17    |
| Smoking status, n (%)*          |                    |                 |         |
| Current smoker                  | 36 (35.3)          | 38 (36.2)       | 0.89    |
| Former smoker                   | 66 (64.7)          | 67 (63.8)       |         |
| COPD severity, n (%)*           |                    |                 |         |
| Very severe                     | 4 (3.9)            | 6 (5.7)         | 0.55    |
| Severe                          | 44 (43.1)          | 44 (41.9)       | 0.86    |
| Moderate                        | 53 (52.0)          | 53 (50.5)       | 0.83    |
| Mild                            | 1 (1.0)            | 2 (1.9)         | 0.58    |
| Pre-BD FVC (L)                  | 3.09±0.71          | 3.14±0.64       | 0.55    |
| Pre-BD FVC (% pred.)            | 90.3±18.89         | 93.3±17.58      | 0.23    |
| Pre-BD FEV₁ (L)                 | 1.4±0.42           | 1.4±0.44        | 0.55    |
| Pre-BD FEV₁ (% pred.)           | 45.8±13.23         | 47.5±13.98      | 0.37    |
| Pre-BD FEV₁/FVC (%)             | 45.3±11.66         | 44.9±11.11      | 0.83    |
| Post-BD FVC (L)                 | 3.33±0.73          | 3.36±0.67       | 0.72    |
| Post-BD FVC (% pred.)           | 97.3±18.98         | 99.8±19.01      | 0.34    |
| Post-BD FEV₁ (L)                | 1.5±0.43           | 1.6±0.45        | 0.64    |
| Post-BD FEV₁ (% pred.)          | 50.9±13.39         | 52.4±14.42      | 0.44    |
| Post-BD FEV₁/FVC (%)            | 46.7±11.30         | 46.6±11.20      | 0.95    |

COPD, chronic obstructive pulmonary disease; BD, bronchodilator; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 second; n (%), categorical data; mean (SD), continuous data.

*Percentages are based on the number of patients in the respective treatment group; n, number of patients in the respective treatment group or category.
maintained to the end of the study (Fig. 2). Subgroup analyses based on the Korean COPD classification guidelines showed a significant improvement in FEV1 in roflumilast-treated patients relative to placebo irrespective of baseline FEV1. No significant differences in the frequency of COPD exacerbations were observed between groups.

**Safety analysis**

During the treatment period, a higher percentage of patients in the roflumilast group (69.6%) reported AEs than did those in the placebo group (45.7%). AEs related to study medication were reported from 25 patients (24.5%) in the roflumilast group and from five (4.8%) in the placebo group. Eight patients (7.8%) in the roflumilast group and two (1.9%) in the placebo group discontinued the study due to AEs. Serious AEs were reported from nine patients (8.8%) in the roflumilast group and from two (1.0%) in the placebo group. No deaths occurred during the treatment period in either group.

The most common AEs were upper respiratory tract infection, diarrhea, weight loss, and anorexia (Table 3). Routine physical examinations and laboratory tests, including complete blood count, blood chemistry and urine analyses, and electrocardiograms, did not reveal any clinically relevant AEs. The mean change in body weight from baseline to last study visit was -2.0 (2.4) kg in the roflumilast group and +0.1 (2.0) kg in the placebo group (LSMean difference, -2.07, p<0.001).

**Table 2. Change of FEV1 (L) for all Korean COPD Patients and Each Sub-Group**

| Variable | Time span | Roflumilast n | Roflumilast SE (LSMean) | Placebo n | Placebo SE (LSMean) | Difference (roflumilast-placebo) | 95% CI | p value |
|----------|-----------|---------------|-------------------------|-----------|---------------------|-------------------------------|-------|---------|
| All Korean patients | Base to W4 99 | 0.086 | 0.0930 | 103 | -0.041 | 0.0911 | 0.107 | 0.0254 | 0.057, 0.157 | <0.01 |
| | Base to W6 99 | 0.033 | 0.0847 | 103 | -0.074 | 0.0830 | 0.107 | 0.0234 | 0.061, 0.153 | <0.01 |
| Pre-BD FEV1 (L) | Base to W12 99 | 0.049 | 0.0827 | 103 | -0.070 | 0.0810 | 0.119 | 0.0231 | 0.073, 0.164 | <0.01 |
| Post-BD FEV1 (L) | Base to W4 99 | 0.073 | 0.0816 | 103 | -0.027 | 0.0800 | 0.099 | 0.0222 | 0.056, 0.143 | <0.01 |
| | Base to W6 99 | 0.043 | 0.0728 | 103 | -0.055 | 0.0713 | 0.098 | 0.0204 | 0.057, 0.138 | <0.01 |
| | Base to W12 99 | 0.043 | 0.0727 | 103 | -0.006 | 0.0712 | 0.103 | 0.0231 | 0.062, 0.145 | <0.01 |
| Patients with FEV1 (% predicted) ≤60% | Base to W4 70 | 0.100 | 0.1003 | 73 | -0.027 | 0.0970 | 0.127 | 0.0322 | 0.064, 0.191 | 0.01 |
| Pre-BD FEV1 (L) | Base to W6 70 | 0.059 | 0.0924 | 73 | -0.056 | 0.0893 | 0.115 | 0.0298 | 0.056, 0.174 | 0.02 |
| | Base to W12 70 | 0.082 | 0.0906 | 73 | -0.050 | 0.08875 | 0.131 | 0.0294 | 0.073, 0.189 | <0.01 |
| Post-BD FEV1 (L) | Base to W4 70 | 0.113 | 0.0760 | 73 | 0.003 | 0.0735 | 0.110 | 0.0243 | 0.062, 0.158 | <0.01 |
| | Base to W6 70 | 0.084 | 0.0709 | 73 | -0.016 | 0.0686 | 0.100 | 0.0228 | 0.055, 0.145 | <0.01 |
| | Base to W12 70 | 0.093 | 0.0710 | 73 | -0.015 | 0.0688 | 0.108 | 0.0235 | 0.062, 0.155 | <0.01 |
| Patients with 50% <FEV1 (% predicted) ≤60% | Base to W4 23 | 0.147 | 0.0430 | 24 | 0.059 | 0.0424 | 0.087 | 0.0629 | -0.040, 0.214 | 0.17 |
| Pre-BD FEV1 (L) | Base to W6 23 | 0.146 | 0.0400 | 24 | 0.049 | 0.0393 | 0.097 | 0.0584 | -0.021, 0.215 | 0.10 |
| | Base to W12 23 | 0.161 | 0.0411 | 24 | 0.039 | 0.0403 | 0.122 | 0.0599 | 0.001, 0.243 | 0.04 |
| Post-BD FEV1 (L) | Base to W4 23 | 0.110 | 0.0333 | 24 | 0.021 | 0.0324 | 0.089 | 0.0491 | -0.009, 0.186 | 0.07 |
| | Base to W6 23 | 0.112 | 0.0324 | 24 | 0.023 | 0.0315 | 0.089 | 0.0468 | -0.006, 0.183 | 0.06 |
| | Base to W12 23 | 0.122 | 0.0337 | 24 | 0.015 | 0.0326 | 0.107 | 0.0485 | 0.009, 0.205 | 0.03 |
| Patients with 60% <FEV1 (% predicted) ≤80% | Base to W4 28 | 0.083 | 0.0282 | 28 | -0.022 | 0.0296 | 0.085 | 0.0409 | 0.003, 0.167 | 0.04 |
| Pre-BD FEV1 (L) | Base to W6 28 | 0.058 | 0.0235 | 28 | -0.055 | 0.0286 | 0.112 | 0.0368 | 0.038, 0.186 | 0.01 |
| | Base to W12 28 | 0.051 | 0.0261 | 28 | -0.061 | 0.0272 | 0.112 | 0.0377 | 0.036, 0.188 | 0.02 |
| Post-BD FEV1 (L) | Base to W4 28 | 0.036 | 0.0324 | 28 | -0.030 | 0.0343 | 0.066 | 0.0476 | -0.029, 0.162 | 0.17 |
| | Base to W6 28 | 0.029 | 0.0278 | 28 | -0.058 | 0.0291 | 0.086 | 0.0404 | 0.005, 0.168 | 0.04 |
| | Base to W12 28 | 0.009 | 0.0273 | 28 | -0.077 | 0.0288 | 0.087 | 0.0399 | 0.006, 0.167 | 0.03 |

FEV1, forced expiratory volume in 1 second; COPD, chronic obstructive pulmonary disease; BD, bronchodilator; FVC, forced vital capacity; LSMean, least-squares mean adjusted for covariates; SE, standard error; ANCOVA, analysis of covariance. LSMeans, SE of LSMeans, 95% confidence intervals and p-values are based on a repeated measures ANCOVA with factors treatment, baseline value, age, sex, smoking status, time, and treatment by time interaction.
DISCUSSION

The major findings in this study were that roflumilast improved lung function in moderate to very severe Korean COPD patients, and the AE profile was comparable to those reported in other Asian and Western populations. Results from the JADE study, which included a heterogeneous population of Asian patients with COPD from different cultural and ethnic backgrounds in Hong Kong, Malaysia, the Philippines, Taiwan, and South Korea, have already shown that the improvement in lung function and the AE profile in response to roflumilast are similar to those of Western patients with COPD. Differences in ethnicity may affect the pharmacological response to respiratory medications in patients with COPD, as previous studies of asthma-related medications show differences in drug pharmacology between different races, which may contribute to differences in treatment response and AEs. Thus, demonstrating the efficacy and AE profile of roflumilast across different ethnic groups is clinically relevant.

Previous studies have also reported similar improvements in

![Graph A](image1)

![Graph B](image2)

![Graph C](image3)

**Fig. 2.** Pre- and post-bronchodilator mean (SE) FEV$_1$ values from baseline to last visit (last observation carried forward) with roflumilast and placebo for (A) all Korean COPD patients, (B) Korean COPD patients with FEV$_1$ ≤60% predicted, and (C) Korean COPD patients with FEV$_1$ 60–80% predicted. SE, standard error; FEV$_1$, forced expiratory volume in 1 second; COPD, chronic obstructive pulmonary disease.
Pooled analysis of the two roflumilast studies showed significantly greater improvement in FEV<sub>1</sub> after roflumilast treatment was not limited to the Korean COPD group “da,” as patients with FEV<sub>1</sub> 60–80% predicted also showed significantly greater improvement in FEV<sub>1</sub> with roflumilast treatment than did those taking placebo. The beneficial effect of roflumilast on lung function was demonstrated previously in a 6-month study of Western patients with moderate to severe COPD. A pooled analysis of the two roflumilast studies (M2-124 and M2-125) also demonstrated that roflumilast improves lung function regardless of age, smoking status, or geographic region.

FEV<sub>1</sub> is the standard measurement for the diagnosis and staging of COPD and has been used as a primary measurement of lung function in many clinical trials. Although a minimum clinically important difference (MCID) for FEV<sub>1</sub> has not been firmly established, a suggested MCID for FEV<sub>1</sub> is 100–140 mL in patients with COPD. One cross-sectional study reported that a 112-mL difference in FEV<sub>1</sub> was associated with a noticeable improvement of dyspnea in patients with COPD. Bronchodilator-induced improvements in FEV<sub>1</sub> of 75–100 mL are known to improve the quality of life in patients with COPD. In the Towards a Revolution in COPD Health (TORCH) trial, treatment with fluticasone alone and in combination with salmeterol improved the mean FEV<sub>1</sub> by 47 mL and 92 mL, respectively, when compared to placebo. Those FEV<sub>1</sub> improvements were associated with significantly improved quality of life scores and reduced frequency of exacerbations. A recent meta-analysis of eight trials demonstrated that roflumilast significantly improves pre-bronchodilator FEV<sub>1</sub>, (pooled effect size 55 mL; 95% CI 42–68). More importantly, the study showed that roflumilast treatment reduces moderate to severe exacerbations by 27% when compared to placebo. In this study, roflumilast improved FEV<sub>1</sub>, significantly more than placebo in moderate and severe COPD patients. The JADE study did not allow concomitant long-acting bronchodilators and ICS, which might have caused a significant FEV<sub>1</sub> decline (60 mL) during the study period in the placebo group and might have also induced statistically significant differences when compared to the roflumilast-treated group. The recent Roflumilast and Exacerbations in patients receiving Appropriate Combination Therapy (REACT) trial demonstrated that roflumilast improves lung function and reduces exacerbations in patients with severe COPD who are at risk of exacerbations despite ICS/long-acting beta-2 agonist (LABA), even in triple combination with tiotropium. Roflumilast also increased post-bronchodilator FEV<sub>1</sub> from baseline to week 52 more than placebo, with a mean difference of 56 mL (95% CI 38–73 mL). Additional long-term large clinical trials are required to confirm that roflumilast add-on therapy can also contribute to an improved quality of life and reduced frequency of exacerbations in Korean COPD patients.

Differences in COPD phenotypes have been noted between Asian and Western populations. According to one observational study, most Japanese patients with COPD have an emphysema-dominant phenotype, whereas Western patients tend to have a chronic bronchitis phenotype. In the Korean Obstructive Lung Disease (KOLD) cohort, chronic bronchitis was present in about 15% of COPD patients, and the difference in clinical phenotype was found to possibly affect the response to pharmacological treatment. Previous clinical trials in patients with severe or very severe COPD show that roflumilast reduces the frequency of exacerbations in a subset of COPD patients with chronic bronchitis. Regrettably, our study did not have sufficient power to evaluate the effects of treatment on the frequency of exacerbations. Previous history of exacerbation and severity of airflow limitation are the most powerful predictors of future exacerbations. However, a history of exacerbations was not required for inclusion in this study, and the

---

Table 3. Incidence of Adverse Events Affecting at Least 3% of Patients among All Korean COPD Patients

|                      | Roflumilast (n=102) | Placebo (n=105) | p value |
|----------------------|---------------------|-----------------|---------|
| All adverse events   | 71 (69.6)           | 176             | 0.01    |
| Upper respiratory   | 21 (20.6)           | 10 (9.5)        | 0.03    |
| tract infection      |                     |                 |         |
| Diarrhea             | 14 (13.7)           | 14              | 0.01    |
| Weight decrease      | 9 (8.8)             | 9               | 0.01    |
| Anorexia             | 9 (8.8)             | 9               | 0.01    |
| COPD exacerbations   | 9 (8.8)             | 12 (11.4)       | 0.64    |
| Decreased appetite   | 6 (5.9)             | 6               | 0.06    |
| Gastritis            | 5 (4.9)             | 5               | 0.03    |
| Constipation         | 4 (3.9)             | 1 (1.0)         | 0.20    |
| Dizziness            | 4 (3.9)             | 4               | 0.06    |
| Rhinorrhea           | 4 (3.9)             | 4               | 0.21    |

COPD, chronic obstructive pulmonary disease.

---

http://dx.doi.org/10.3349/ymj.2016.57.4.928
majority of our patients had moderate rather than severe COPD. Therefore, more than 90% of patients in both groups completed the 12-week treatment period without experiencing a COPD exacerbation. Consequently, due to the study duration, the effect of roflumilast on the exacerbation rate could not be confirmed in this trial.

Although roflumilast has been generally well-tolerated in clinical trials to date, it does contribute to adverse effects. In a pooled analysis of over 8000 patients participating in a clinical trial, the incidence of AEs and discontinuation of treatment was significantly more frequent in patients taking roflumilast than in those taking placebo. In our study, gastrointestinal (diarrhea, nausea, and decreased appetite), nervous system (headache, dizziness, and tremor, and insomnia), and weight loss AEs were significantly more frequent in patients taking roflumilast than in those taking placebo. The incidence of these AEs in our Korean patients with COPD was similar to those reported in other Asian and Western studies. However, the increased incidence of serious AEs associated with taking roflumilast, such as atrial fibrillation, psychiatric disturbance, and possible carcinogenesis, are considerable concerns. Phase IV post-marketing studies that are currently ongoing will reveal the long-term safety profile of roflumilast. Theophylline, a non-selective PDE inhibitor, has a mechanism of action comparable to roflumilast. Although theophylline has a small therapeutic ratio and wide range of toxic side effects, it is still widely used in Asian countries, including Korea. Theophylline also improves lung function and respiratory symptoms and reduces exacerbations in patients with COPD. In a meta-analysis of 20 randomized controlled trials, the mean improvement in FEV1 with theophylline was 100 mL more than with placebo, similar to what we found with roflumilast in this study. Clinical studies that compare the efficacy and safety of theophylline and roflumilast are needed to determine which medication has a better risk-benefit ratio.

This study had several limitations. Firstly, this study did not include patient-centered outcomes, such as dyspnea, quality of life, and exercise capacity as indicators of efficacy. Secondly, as all included patients except one were male, our conclusions may not be applicable to female Korean COPD patients. Another limitation was that concomitant treatment with long-acting bronchodilators and/or ICS was not permitted during the study. The effect of roflumilast when given as an add-on therapy to these medications is currently unknown. However, a large randomized controlled trial is currently investigating this question.

In conclusion, roflumilast significantly improved lung function and had a tolerable safety profile in Korean patients with COPD irrespective of the severity of airflow limitation.

ACKNOWLEDGEMENTS

This work was supported by Takeda Pharmaceuticals International GmbH. Primary data management and statistical analysis were conducted by Manja Brose, Takeda Pharmaceuticals International GmbH. The authors would like to thank all of the Korean investigators who recruited and treated patients in this study.

Conflict of interest statement

YM Oh received payment for lecturing from MSD Korea, AstraZeneca Korea, Boehringer Ingelheim Korea, Novartis, DongWha, Takeda, and GSK Korea. SD Lee received support from Takeda Pharmaceuticals International GmbH for travel to an investigator meeting. He received payment from Takeda Pharmaceuticals International GmbH for attendance at an advisory board. He also received honoraria from GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim.

REFERENCES

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e42.
2. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412.
3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2014. [accessed on 2015 May]. Available at: http://www.goldcopd.org/uploads/users/les/GOLD_Report2014_ Feb07.pdf.
4. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
5. Drummond MB, Dassenbroek EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-16.
6. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011;163:53-67.
7. Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbroeker D, Bethke TD. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71.
8. Calverley PM, Sanchez-Toril F, McVor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61.
9. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94.
10. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703.
11. Rennard SI, Calverley PM, Goehring UM, Bredenbroeker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast—the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18.
12. Obi Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and
13. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008;84:417-23.
14. Lee SD, Hui DS, Mahayiddin AA, Roa CC Jr, Kwa KH, Goehring UM, et al. Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial. Respirology 2011;16:1249-57.
15. Pang JA, Zhang YG, Swaminathan R. The pharmacokinetics and efficacy of slow-release theophylline with asymmetric dosing in asthmatic Chinese. Chest 1989;93:785-9.
16. Choudhry S, Ung N, Avila PC, Ziv E, Nazario S, Casal J, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 2005;171:563-70.
17. Cazzola M, Matera MG. Safety of long-acting beta2-agonists in the treatment of asthma. Ther Adv Respir Dis 2007;1:35-46.
18. Zheng J, Yang L, Zhou X, Zhao L, Hui F, Wang H, et al. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. Chest 2014;145:44-52.
19. Hwang YI, Park YB, Oh YM, Lee JH, Kim TH, Yoo KH, et al. Comparison of Korean COPD guideline and GOLD initiative report in term of acute exacerbation: a validation study for Korean COPD guideline. J Korean Med Sci 2014;29:1108-12.
20. Hanania NA, Calverley PM, Dransfield MT, Karpel JP, Brose M, Zhu H, et al. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med 2014;108:366-75.
21. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;32:416-69.
22. Redelmeier DA, Goldstein RS, Min ST, Hyland RH. Spirometry and dyspnea in patients with COPD. When small differences mean little. Chest 1996;109:1163-8.
23. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-9.
24. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015;385:857-66.
25. Oh YM, Bhome AB, Boonsawat W, Gunasekera KD, Madegedara D, Idolor L, et al. Characteristics of stable chronic obstructive pulmonary disease patients in the pulmonology clinics of seven Asian cities. Int J Chron Obstruct Pulmon Dis 2013;8:31-9.
26. Tatsumi K, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y, Kuriyama T; Respiratory Failure Research Group in Japan. Clinical phenotypes of COPD: results of a Japanese epidemiological survey. Respirology 2004;9:331-6.
27. Lee JS, Kim SO, Seo JB, Lee JH, Kim EK, Kim TH, et al. Longitudinal lung volume changes in patients with chronic obstructive pulmonary disease. Lung 2013;191:405-12.
28. Lee JH, Lee YK, Kim EK, Kim TH, Huh JW, Kim WJ, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010;104:542-9.
29. Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary disease. J Korean Med Sci 2011;26:379-85.
30. Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Different therapeutic responses in chronic obstructive pulmonary disease subgroups. Int J Tuberc Lung Dis 2011;15:1104-10.
31. Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Response patterns to bronchodilator and quantitative computed tomography in chronic obstructive pulmonary disease. Clin Physiol Funct Imaging 2012;32:12-8.
32. Yoo JW, Hong Y, Seo JB, Chae EJ, Ra SW, Lee JH, et al. Comparison of clinico-physiologic and CT imaging risk factors for COPD exacerbation. J Korean Med Sci 2011;26:1606-12.
33. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
34. Murciano D, Auclair MH, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989;320:1521-5.
35. Ram FS, Jones PW, Castro AA, De Brito JA, Atallah AN, Lacasse Y, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002:CD003902.